Fig. 1

Pharmacokinetic profile and pharmacodynamic activity. A Semi-logarithm mean serum concentration–time profiles of SHR-1701. Error bars represent standard deviation. B PD-1 target occupancy following SHR-1701 treatment. There was a sharp decrease in the patient in the 1 mg/kg every 3 weeks group on C5D1 before administration, which might be caused by delayed treatment (interval between C4D1 and C5D1, 27 days). The patient withdrew from the study after C5D1. In the 10 mg/kg every 3 weeks group, PD-L1 target occupancy of 1 patient decreased to 25% on C5D1, but reached saturated level before administration on C9D1. All the remaining patients had a sustained and saturated PD-L1 target occupancy throughout the study. C TGF-β1 concentrations following SHR-1701 treatment. The free TGF-β1 level in the patient in the 1 mg/kg every 3 weeks group sharply increased on C5D1 before administration. In addition to treatment delay, low dose level might be the reason. PD-L1, programmed death ligand 1; TGF-β1, transforming growth factor-β 1; EOT, end of treatment; EOS, end of study